AN2 Therapeutics Inc (ANTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.64M
Last updated: Nov 17, 2026 at 11:04 AM ET
AN2 Therapeutics Inc (ANTX) Competitors
The companies most similar to AN2 Therapeutics are Upstream Bio (UPB), Invivyd (IVVD) and Whitehawk Therapeutics (WHWK). By market cap, AN2 Therapeutics ranks 4th of the 13 companies on this page; Vanda Pharmaceuticals (VNDA) is the largest at $241.27M.
Peer Comparison
ANTX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics (ANTX) | $172.64M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Whitehawk Therapeutics, Inc. (WHWK) | $180.57M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Compass Therapeutics Inc. (CMPX) | $139.35M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| MacroGenics Inc (MGNX) | $140.60M | N/A | 1.2x | -36.6% | -108.7% | -64.8% | 0.00% |
| Vanda Pharmaceuticals Inc (VNDA) | $241.27M | N/A | 1.0x | -119.9% | -84.7% | 24.1% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zentalis Pharmaceuticals Llc (ZNTL) | $167.05M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Eledon Pharmaceuticals Inc (ELDN) | $178.63M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Protara Therapeutics Inc (TARA) | $155.77M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $155.76M | N/A | 10.2x | 0.0% | -68.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to AN2 Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Whitehawk Therapeutics, Inc. (WHWK) | Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. | WHWK competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Compass Therapeutics Inc. (CMPX) | Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple... | CMPX competitors |
| MacroGenics Inc (MGNX) | MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. | MGNX competitors |
| Vanda Pharmaceuticals Inc (VNDA) | Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. | VNDA competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Zentalis Pharmaceuticals Llc (ZNTL) | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment... | ZNTL competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Eledon Pharmaceuticals Inc (ELDN) | Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases... | ELDN competitors |
| Protara Therapeutics Inc (TARA) | Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment... | TARA competitors |
Frequently Asked Questions About ANTX
Who are AN2 Therapeutics' main competitors?
The companies most similar to AN2 Therapeutics include Upstream Bio (UPB), Invivyd (IVVD), Whitehawk Therapeutics (WHWK), Innate Pharma (IPHA) and Compass Therapeutics (CMPX), listed from the closest match.
Who is AN2 Therapeutics' biggest competitor?
Vanda Pharmaceuticals (VNDA) is the largest of the similar companies at $241.27M; Upstream Bio (UPB) is the closest match by business profile, size, sector and industry.
How does ANTX stock compare with its competitors?
ANTX's net margin is 0.0% against a peer median of 0.0%.
Which of AN2 Therapeutics' competitors pays a higher dividend?
AN2 Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is AN2 Therapeutics bigger than its competitors?
No. AN2 Therapeutics is 4th by market cap among the 13 companies on this page; the largest is Vanda Pharmaceuticals (VNDA) at $241.27M.
ANTX pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts